

## Index

- acetylcholine (Ach), 47, 51–52, 96  
 acetylcholine-mediated  
 micro-vasodilatation, 92  
 acetylcholine-mediated skin  
 microvascular response, 92, 93  
 acute fatty liver, 241  
 advanced gestation, 6  
 Afro-Caribbean women, 143  
 age-related macular  
 degeneration (AMD), 174  
 albumin measurements, 135–136  
 American Heart  
 Association, 233  
 anatomy of microcirculation, 42–43  
 angiogenesis, 172*f*, 172, 174  
 angiotensin type 1 receptor  
 (AT1-AA), 194  
 Antagonistic Pleiotropy  
 Theory of aging, 230–231  
 anthracyclines, 219, 220–221, 223  
 anti-angiogenic therapy, 174  
 anti-hypertensive agents, 149, 151  
 aortic root, 27  
 aortic systolic blood pressure  
 (SBP Ao), 71, 109  
 appropriate for gestational age  
 fetuses (AGAf), 207, 209*f*,  
 209, 213, 215*f*  
 arterial compliance, 70–71  
 arterial function assessment  
 techniques  
 arterial stiffness, 103–108  
 arterial waveform  
 characteristics, 108–110,  
 109*f*  
 endothelial function,  
 102–103, 104–106*f*  
 flow mediated dilatation,  
 102–103  
 arterial function in  
 pathological pregnancy  
 changes in, 69–74, 70–71*f*,  
 72*f*  
 fetal growth restriction, 74–75  
 gestational diabetes, 75–76  
 overview of, 69  
 preterm birth and, 75  
 arterial resistivity index, 37  
 arterial stiffness  
 assessment techniques, 101,  
 103–108  
 in pathological pregnancies,  
 70–71*f*, 72*f*, 74, 101  
 pulse wave velocity, 107*f*, 108  
 arterial waveform, 101,  
 108–110, 109*f*  
 Arterigraph device, 108  
 arteriolar to venular ratio  
 (AVR), 48*f*, 48  
 arterioles, 42  
 arteriovenous shunting, 14  
 aspirin  
 adverse effects of, 166  
 effect on placentation,  
 164–165  
 effect on platelet/endothelial  
 function, 164  
 mechanism of action, 161,  
 162*f*  
 optimal gestation for  
 starting, 167  
 optimizing dose of, 168  
 patients identified for, 167  
 pharmacological properties,  
 162–163  
 preeclampsia prevention  
 with, 163–166  
 unresolved clinical  
 dilemmas, 167–168  
 Asymmetric dimethylarginine  
 (ADMA), 181–182  
 atherosclerosis-related  
 cardiovascular  
 disease, 102  
 atrial geometry, 27  
 atrial natriuretic hormone  
 ( $\alpha$ -ANP), 18  
 atrial natriuretic peptide  
 (ANP), 63  
 augmentation index (AIx), 26,  
 71–72, 73, 108–110  
 autonomic nervous system, 36  
 Barker hypothesis, 61  
 baroreceptor activation, 14  
 basal capillary density  
 (BCD), 44  
 basic fibroblast growth factor  
 (bFGF), 172  
 B-cell lymphoma, 224  
 BeWo cells, 164  
 bilateral uterine arterial  
 notching, 96  
 biochemical “stress” response, 1  
 bioelectrical impedance  
 analysis (BIA), 138  
 bioimpedance in  
 echocardiography,  
 127–128  
 bioreactance in  
 echocardiography,  
 127–128  
 birth weight, 3–4, 39  
 biventricular systolic  
 dysfunction, 8  
 Bland-Altman analysis, 116  
 blood cell velocity, 94  
 blood pressure (BP)  
 aortic systolic blood  
 pressure, 71, 109  
 brachial cuff-based  
 measurements, 110  
 cardiac function and, 24  
 diastolic blood pressure,  
 24, 235  
 effects of, 18–19  
 excessive reduction in, 148  
 systolic blood pressure  
 (SBP), 24, 71, 74, 109  
 body fat mass distribution, 80  
 body mass index (BMI), 24, 80,  
 207–208, 231  
 brightness-mode imaging, 121  
 calcium channel blockers  
 (CCB), 150–151  
 cancer survivors, 224–226,  
 225*f*  
 capillaries. *See also*  
 microcirculation  
 basal capillary density, 44  
 blood cell velocity, 94

- capillaries (cont.)  
 continuous capillaries, 42  
 density of, 51  
 discontinuous capillaries, 42  
 erythrocytes in, 44  
 fenestrated capillaries, 42  
 function of, 36  
 laser Doppler flowmetry, 93  
 maximal capillary density, 44  
 video capillaroscopy, 44  
 capillary density (CD), 43  
 cardiac catheterization, 101  
 cardiac dysfunction in hypertensive pregnancy  
 classification of, 80  
 left atrial dimensions/functions, 82  
 left ventricular dysfunction/geometry, 82–83  
 long term outcome, 83–84  
 maternal heart role in, 80  
 systolic function, 81–82  
 cardiac endothelial nitric oxide synthase (eNOS), 28  
 cardiac function. *See also* chemotherapy and cardiovascular function  
 atrial geometry, 27  
 blood pressure, 24  
 cardiac output, 25  
 diastolic function, 30  
 diastolic/systolic dimensions, 26  
 electrocardiographic changes, 27–28  
 global arterial compliance, 26  
 heart rate, 24–25  
 heart remodeling, 26  
 indirect filling pressure indices, 31  
 labor and delivery demands, 31  
 left ventricular mass, 27  
 left ventricular outflow, 27  
 left ventricular wall thickness, 27  
 longitudinal function, 30  
 metabolism and, 28  
 mitral inflow, 30  
 molecular mechanisms, 28–29  
 myocardial deformation, 29, 30  
 radial function, 29  
 right ventricular dimensions/mass, 27  
 systemic vascular resistance, 25–26  
 systolic function, 29  
 tissue Doppler imaging, 30  
 uteroplacental flow, 31  
 cardiac geometry in advanced gestation, 6  
 cardiac maladaptation, 5  
 cardiac output (CO)  
 echocardiography and, 120, 121*t*  
 labor and delivery demands, 31  
 ventricular performance and, 25  
 Cardiac Output/Pulse Pressure (CO/PP) ratio, 70  
 cardiotoxicity with chemotherapy, 220*t*, 221, 222*t*, 223  
 cardiovascular and volume receptors in pregnancy  
 arterial bed effects, 15, 17*f*  
 blood pressure effects, 18–19  
 early identification of, 21  
 generalized vascular relaxation, 14, 15*f*  
 maternal heart effects, 20*f*, 21  
 pregnancy-specific changes, 14–21  
 preterm birth, 239–240  
 regional blood flow effects, 21  
 systemic microcirculation, 17*f*, 18, 22  
 systemic vascular relaxation, 15, 16*f*, 16*t*, 22  
 venous bed effects, 18, 19*f*  
 volume homeostasis effects, 19–20  
 cardiovascular disease  
 atherosclerosis-related cardiovascular disease, 102  
 mortality/morbidity, 69  
 preeclampsia as, 229  
 therapeutic angiogenesis, 174  
 cardiovascular disease after pregnancy  
 acute fatty liver, 241  
 cerebrovascular disease, 236–238  
 fetal growth restriction, 240  
 follow-up to complicated pregnancies, 242–243  
 gestational diabetes mellitus, 240–241  
 history of, 230  
 hypertensive disorders of pregnancy, 233–239  
 interpregnancy interval, 232, 233*f*  
 ischemic heart disease, 235, 236*f*, 237*f*, 237*t*  
 maternal age, 232–233  
 mechanisms leading to, 242  
 miscarriages, 241  
 mortality, 238–239*f*  
 number of pregnancies, 230, 231–232*f*  
 other complications, 241  
 placental abruption, 241  
 pregnancy complications and, 233–234, 234*f*  
 pregnancy in general, 230–233  
 preventative programs, 243  
 cardiovascular involvement, 6–10, 7–8*t*  
 heart effects, 20*f*, 21  
 heart role in cardiac dysfunction, 80  
 pre-hypertension, 9  
 Carotid Femoral Pulse Wave Velocity (cfPWV), 71, 73  
 central retinal arteriolar equivalent (CRAE), 48*f*, 48  
 central retinal venular equivalent (CRVE), 48*f*  
 central systolic pressure (CSP), 74  
 cerebrovascular disease, 236–238  
 cGMP-specific phosphodiesterase type 5 (PDE5) inhibitor, 187  
 chamber filling pressure, 31  
 chemotherapy and cardiovascular function administered during pregnancy, 221–224  
 in cancer survivors, 224–226, 225*f*  
 cardiotoxicity with, 220*t*, 221, 222*t*  
 fetal effects, 223–224  
 maternal effects, 223

- pharmacokinetics of, 222–223  
 cholesterol levels, 234  
 chronic hypertension, 74, 80, 141, 144, 147–148, 235  
 chronic inflammation, 92  
 circulatory changes, 59*f*  
 class 2 cardiotoxicography (CTG), 205  
 collagen, 34  
 Complior System, 108  
 congestive heart failure, 221  
 continuous capillaries, 42  
 convective oxygen transports, 43  
 conventional echo assessment, 9  
 cyclic guanosine 3', 5'-monophosphate (cGMP), 195  
 cyclooxygenase enzymes (COX-1 and COX-2), 161  
 cystathionine-b-synthase (CBS), 199  
 cystathionine-glyase (CSE), 199  
 cytotoxic treatment, 219  
 cytotrophoblast, 163  
  
 dextran in plasma volume measurements, 136–137  
 diastolic blood pressure (DBP), 24, 235  
 diastolic function, 30, 39  
 diffuse intravascular coagulation (DIC), 193  
 diffuse pathological arterial function, 70–71*f*, 72*f*, 74  
 diffusion and red blood cells, 43, 50  
 dilution method of measurement, 135  
 direct stimulation in venous physiology, 35  
 discontinuous capillaries, 42  
 Disposable Soma Theory of aging, 230–231  
 Doppler shift (wavelength change), 46  
 Doppler sonography. *See also* venous Doppler sonography; venous Doppler waveform electrocardiogram and, 113–114  
 laser Doppler flowmetry, 46, 93  
 laser Doppler imaging, 46–47  
 laser Doppler perfusion imaging, 46, 47  
 laser Doppler perfusion monitoring, 46  
 suprasternal Doppler, 125–126  
 uterine artery Doppler screening, 4–5, 165, 210–211, 212*f*  
 dyes in plasma volume measurements, 135–136  
 Dynamic Vessel Analyzer (DVA), 48, 92, 95  
 dyslipidemia, 229, 242  
  
 early-onset preeclampsia, 84, 89, 167, 185*f*, 186, 206  
 eccentric cardiac hypertrophy, 26  
 echocardiography bioimpedance and bioreactance, 127–128  
 cardiac output and, 120, 121*t*  
 finger plethysmography, 128  
 inert gas rebreathing, 126–127  
 left ventricular (LV) outflow tract measurement, 125*f*, 125  
 magnetic resonance imaging, 126, 127*f*  
 measuring during exercise, 128–129  
 Simpson's (modified) biplane technique, 122*f*  
 single plane B-mode 4-chamber view, 122, 123*f*  
 suprasternal Doppler, 125–126  
 Teichholz method and, 121  
 3-D methods, 123–125  
 triplane analysis, 122, 124*f*  
 elastin, 34  
 electrocardiogram (ECG), 21, 27–28, 37, 113–114  
 electrocardiographic changes, 27–28  
 electrophysiologic P-wave of ECG, 37  
 elevated peripheral resistance, 81–82  
  
 endothelial cells, 36, 42, 163–164  
 endothelial dysfunction cardiovascular disease after pregnancy, 242  
 preeclampsia and, 92, 95–96, 181, 194  
 role of, 194–195  
 Sildenafil citrate, 196–197  
 endothelial function, 102–103, 104–106*t*, 164  
 endothelial glycocalyx, 43  
 endothelial nitric oxide synthase, 28  
 endothelial surface layer, 42  
 endothelial release of prostacyclin and nitric oxide, 14  
 endothelin-1 (ET-1), 195, 199–200  
 endothelin receptor antagonists, 199–200  
 environmental risk factors for preeclampsia, 5–6  
 erythrocytes in capillaries, 44  
 Evans Blue (T-1825) dye, 136  
 E-wave velocity to myocardial  $e'$  velocity ( $E/e'$  ratio), 82  
 extracellular signal-regulated kinase (ERK1/2) phosphorylation, 28  
  
 FE-labelled transferrin, 137  
 fenestrated capillaries, 42  
 fetal aneuploidy, 2  
 fetal growth restriction (FGR) arterial function in pathological pregnancy, 74–75  
 birth weight and, 3–4  
 cardiovascular disease after pregnancy, 240  
 causality of, 1  
 clinical risk factors, 5  
 conventional beliefs, 1, 2*f*  
 late-onset uteroplacental dysfunction, 9–10  
 placental dysfunction, 13  
 placental growth factor, 5  
 placental histology, 2–3  
 plasma volume and, 63  
 post-partum cardiovascular legacy, 9  
 pregnancy-induced hypertension, 81–82

- fetal growth (cont.)  
 uterine artery Doppler screening, 4, 5  
 VEGF gene therapy and, 171, 174–178, 176*f*, 177*f*
- feto-placental blood flow, 93
- “fight or flight” back-up mechanism, 20
- Filtrass strain gauge  
 plethysmography, 94
- finger plethysmography, 38
- flicker-induced dilatation (FID), 49
- flow mediated dilatation (FMD), 72–73, 102–103
- Framingham Heart Study, 231
- Frank-Starling mechanism, 21
- gadolinium contrast agent, 126
- generalized vascular relaxation, 14, 15*f*
- genetic risk factors for preeclampsia, 5–6
- gestation. *See* normal pregnancy
- gestational diabetes mellitus (GDM), 9, 75–76, 240–241
- gestational hypertension, 13, 80, 82–83, 88–89, 206. *See also* hypertensive disorders of pregnancy
- global arterial compliance, 26
- glomerular filtration rate (GFR), 20
- glyceryl trinitrate (GTN), 75, 152, 183–184, 197–198
- glycocalyx, 43
- Gq signalling pathway, 28–29
- GSNO reductase (GSNOR), 187–188
- healing effect of a successive pregnancy, 238
- heart rate (HR), 24–25, 26
- heart remodelling, 26
- HELLP syndrome, 13, 50, 186, 193
- hepatic veins (HV) waveforms, 87*f*, 87
- heterogeneity index (HI), 43, 45
- high-resistance uterine circulation, 1
- hydralazine, 151–152
- hydrogen sulfide (H<sub>2</sub>S), 199
- hydroxyethyl starch (HES), 137
- hyperdynamic capillary flow, 51
- hyperdynamic circulation, 14
- hypertension  
 chronic hypertension, 74, 80, 141, 144, 147–148, 235  
 gestational hypertension, 13, 80, 82–83, 88–89, 206  
 maternal pre-hypertension, 9  
 non-proteinuric gestational hypertension, 88–89  
 overview of, 234–235  
 salt-sensitive hypertension, 151
- hypertensive disorders of pregnancy (HDP). *See also* cardiac dysfunction in hypertensive pregnancy; gestational hypertension  
 appropriate for gestational age fetuses, 209*f*, 209, 213, 215*f*  
 cardiovascular disease after pregnancy, 233–239  
 chemotherapy induced, 221, 222*t*  
 chronic hypertension, 74, 80, 141, 144, 147–148  
 classification of, 80  
 clinical diagnoses of, 210–213, 211*f*, 212*f*, 214*f*  
 clinical spectrum, 142*f*, 142–144  
 epidemiology of, 206–207  
 fetal diagnosis, 211, 212*f*  
 gestational hypertension, 80  
 hypertension and, 234–235  
 intrauterine growth restriction, 209*f*, 209, 213, 215*f*  
 intravenous anti-hypertensives, 151–152  
 management of, 144–147, 145*t*, 148, 149  
 maternal diagnosis, 212–213, 214*f*  
 mortality and morbidity, 69–70  
 novel therapies, 152–154  
 oral treatment for, 149–151  
 pharmacological treatment of, 149  
 placenta pathology, 210, 211*f*  
 post-partum considerations, 154–155  
 with preeclampsia, 230
- pregnancy-induced hypertension, 148–149  
 secondary hypertension, 147  
 uterine artery Doppler screening, 210–211, 212*f*
- hypertrophy, 26, 27, 28–29
- hypoperfusion, 1
- impaired placentation theory, 1, 5, 193–194
- Incident Dark Field (IDF) illumination technique, 46
- indicator dilution technique, 135
- indirect stimulation in venous physiology, 35–36
- indocyanine green (cardio-green) dye, 136
- inert gas rebreathing, 126–127
- inflammatory cascade, 229
- inflammatory cytokines, 195
- insulin resistance, 242
- interleukin (IL)-3  
 production, 164
- International Committee for Standardization in Haematology (ICSH), 136
- International Society for the Study of Hypertension in Pregnancy (ISSHP), 80, 143
- interpregnancy interval, 232, 233*f*
- intraclass correlation coefficient (ICC), 115, 116
- intrauterine growth restriction (IUGR)  
 Doppler findings, 89, 93, 205  
 induction of labor, 205–206  
 predicting preeclampsia, 209*f*, 209  
 trophoblastic invasion, 208
- intravenous anti-hypertensives, 151–152
- intraventricular hemorrhage, 166
- invasive cardiac catheterization, 101
- in vivo microscopic measurement, 113
- iodine in plasma volume measurements, 136
- ischemic heart disease, 235, 236*f*, 237*f*, 237*t*
- isosorbide dinitrate (ISDN), 183, 184, 198

- labetalol properties, 150,  
151–152, 154
- labor and delivery demands, 31
- large for gestational age  
(LGA), 3–4
- L-arginine, 94, 153, 186–187,  
195–196
- laryngeal edema, 194
- laser Doppler flowmetry (LDF)  
Doppler flowmetry, 93  
Doppler imaging, 46–47  
Doppler perfusion imaging,  
46, 47  
Doppler perfusion  
monitoring, 46  
speckle contrast  
imaging, 47
- late-onset disorders, 1, 213
- late-onset preeclampsia, 84, 89,  
206, 213, 216
- late-onset uteroplacental  
dysfunction, 9–10
- L-citrulline, 196
- left atrial dimensions/  
functions, 82
- left ventricular diastolic  
dysfunction, 6–8, 80,  
125*f*, 125  
dysfunction/geometry,  
82–83  
end-diastolic (LVED)  
diameter, 26  
end-systolic (LVES)  
diameter, 26  
global diastolic  
dysfunction, 82  
left ventricular mass, 27  
left ventricular  
outflow, 27  
systolic function, 29  
wall thickness, 27
- lipid parameters, 242
- local arterial stiffness, 108
- longitudinal function, 30
- low-dose aspirin, 155
- low-molecular-weight  
heparin, 144
- low peripheral resistance, 81
- low plasma volume, 61–62
- low-resistance uterine  
circulation, 4
- magnetic resonance imaging  
(MRI), 126, 127*f*
- mammalian pregnancy and  
parturition, 13
- maternal age and  
cardiovascular disease,  
232–233
- maternal cardiac dysfunction, 3
- maternal-fetal medicine  
(MFM) and preeclampsia  
intrauterine growth  
restriction, 209*f*, 209  
overview of, 207–209,  
209*f*  
predictions of, 207, 208*t*
- maximal capillary density  
(MCD), 44, 51
- maximum arteriolar  
constriction component  
(MAC), 49
- maximum flow velocity (MxV),  
113, 115
- mean arterial pressure (MAP),  
24, 142, 167
- metabolic syndrome, 242
- metabolism and cardiac  
function, 28
- methyldopa transmitter, 150
- microcirculation. *See also*  
capillaries  
anatomy and physiology,  
42–43  
Laser Doppler imaging,  
46–47  
methods of assessing, 43–44  
in normal pregnancy, 51–52  
O2 C device, 48  
potential and importance of,  
50–51  
retinal vessel analysis, 48*f*, 49*f*  
video capillaroscopy, 44  
videomicroscopes, 45–46
- microvascular findings in  
pathological pregnancy  
analysis at preeclampsia  
onset, 93–96, 95*f*  
analysis prior to  
preeclampsia onset, 96  
postpartum analysis in  
preeclampsia, 92–93
- microvascular flow index  
(MFI), 43, 45, 51
- Millar strain gauge transducer  
(SPT-301), 109
- minimum flow velocity (MnV),  
113, 115
- miscarriages, 224, 241
- mitochondrial aldehyde  
dehydrogenase (mtADH),  
183, 184
- mitral inflow, 30
- molecular mechanisms, 28–29
- mortality and cardiovascular  
disease, 238*f*–239*f*
- myocardial deformation, 27,  
29, 30
- myofibrillar loss, 220
- myofibrils, 29
- naifold capillaroscopy, 51
- National Health and Nutrition  
Examination Survey  
National Epidemiologic  
Follow-up Study  
(NHEFS), 231
- National High Blood Pressure  
Education Program  
(NHBPEP), 142, 216
- National Institute of Clinical  
Excellence (NICE),  
142, 154
- neonatal birth weight, 39
- nifedipine properties, 150
- nitric oxide (NO)  
bioavailability deficiency,  
36, 152  
endothelial injury and  
dysfunction, 102  
enhanced sensitivity to, 96  
gestational diabetes and, 76  
platelet inhibition, 162  
synthases, 195–196  
vascular endothelium, 195  
vasodilation and, 195
- nitric oxide (NO) donors in  
preeclampsia  
background, 181–183  
glyceryl trinitrate, 183–184  
GSNO reductase, 187–188  
isosorbide dinitrate, 183, 184  
L-arginine, 186–187,  
195–196  
L-citrulline, 196  
organic nitrates, 183  
overview of, 183–186,  
197–199  
plasma volume expansion,  
198–199  
Sildenafil citrate, 187,  
196–197  
therapeutic strategies,  
195–199
- nitroglycerine, 183
- nitroprusside (SNP), 47
- non-proteinuric gestational  
hypertension, 88–89

- normal pregnancy. *See also* venous compartment in normal pregnancy  
 microcirculation in, 51–52  
 plasma volume changes, 63, 64f  
 VEGF and, 172f, 172, 173
- normotensive formerly preeclamptic women, 58, 60
- nuclear factor-kB (NF $\kappa$ B) activation, 162
- O2 C device, 48
- estrogen, 25–26, 28
- oral treatment for hypertensive disorders, 149–151
- orthogonal polarization spectral (OPS), 45
- orthostasis, 36
- oscillometric technique, 109
- oxidative stress, 92
- oxygen consumption of heart, 28
- parasympathetic nervous system, 35
- PARIS Collaborative Group, 166
- pathological pregnancy. *See* arterial function in pathological pregnancy; microvascular findings in pathological pregnancy
- pentaerithrityltetranitrate (PETN), 152–153, 184
- perfused boundary regions (PBR), 45
- pericardial disease, 221
- peripheral artery disease, 174
- peripheral edema, 128
- personal risk factors, 208
- pharmacokinetics of chemotherapy, 222–223
- pharmacological treatment of hypertensive disorders, 149
- phosphodiesterase inhibitors, 153
- physiology of microcirculation, 42–43
- placental abruption, 229, 241  
 growth factor, 5, 163, 173, 182–183  
 hormones, 28  
 ischemia, 163  
 protein-13, 167
- placenta pathology in HDP, 210, 211f
- placentation and aspirin, 164–165
- plasma levels of sEng, inhibin-A, activin-A, pentraxin-3 (PTX3), 167
- plasma volume changes  
 importance of, 63  
 origin of low plasma volume, 61–62  
 throughout gestation, 63, 64f  
 venous reserves, 59–61, 60f
- plasma volume expansion (PVE) and vasodilators  
 endothelin receptor antagonists, 199–200  
 hydrogen sulfide, 199  
 nitric oxide and, 195, 198–199  
 preeclampsia, 193–194  
 therapies targeting vasodilation, 195
- plasma volume measurements  
 albumin, 135–136  
 bioelectrical impedance analysis, 138  
 dextran, 136–137  
 dilution method, 135  
 dyes, 135–136  
 FE-labelled transferrin, 137  
 hydroxyethyl starch, 137  
 indicator dilution technique, 135  
 iodine, 136
- platelet function analyzer (PFA-100), 164, 168
- plethysmography, 113
- preeclampsia (PE). *See also* maternal-fetal medicine (MFM) and preeclampsia; nitric oxide (NO) donors in preeclampsia; temporal classification of preeclampsia  
 altered cardiac geometry, 79  
 birth weight and, 3–4  
 as cardiovascular disease, 229  
 causality of, 1  
 conventional beliefs, 1, 2f  
 diffuse pathological arterial function, 70–71f, 72f, 74  
 early-onset preeclampsia, 84, 89, 167, 185f, 186, 206
- endothelial dysfunction and, 92, 95–96, 181  
 environmental/genetic risk factors, 5–6  
 epidemiology of, 206–207  
 impaired placentation theory, 193–194  
 intrauterine growth restriction (IUGR), 209f, 209, 213, 215f  
 large for gestational age, 3–4  
 late onset preeclampsia, 84, 89, 206, 213, 216  
 left ventricular dysfunction/geometry, 83  
 maternal cardiovascular involvement in, 6–10, 7–8f  
 microvascular analysis at onset, 93–96, 95f  
 microvascular analysis prior to onset, 96  
 microvascular postpartum analysis in, 92–93  
 pathophysiology of, 163–164  
 placental dysfunction, 13  
 placental growth factor, 5  
 placental histology, 2–3  
 post-partum cardiovascular legacy, 9  
 prevention with aspirin, 163–165  
 renal function impairment, 230  
 uterine artery Doppler screening, 4, 5, 165  
 vascular resistance and, 70  
 VEGF role in, 171
- pregnancy-associated plasma protein-A (PAPP-A), 74, 167
- pregnancy complications and cardiovascular disease, 233–234, 234f
- pregnancy-induced eccentric cardiac hypertrophy, 26
- pregnancy-induced hypertension (PIH), 28–29, 148–149. *See also* hypertensive disorders of pregnancy
- pre-pregnancy low plasma volume, 63
- presystolic velocity (PSV), 115
- preterm birth (PTB), 75, 229, 239–240
- progesterone, 19, 25–26, 28

- prolactin, 28  
 prostaglandin, 25–26  
 prostanoid prostacyclin (PGI<sub>2</sub>), 161  
 prothrombotic risk factors, 208  
 pseudovasculogenesis, 163, 172*f*, 172  
 pulmonary artery catheterization (PAC), 120, 194  
 pulsatile component in systemic vascular resistance, 25  
 pulse pressure (PP), 72  
 pulse transit time, 38  
 pulse wave velocity (PWV), 71–72, 73, 107*f*, 107–108  
   Carotid Femoral Pulse Wave Velocity (cfPWV), 71, 73  
  
 radial function, 29  
 randomized trials (RCTs), 161, 165, 174  
 red blood cells (RBC), 43, 50  
 regional arterial stiffness, 21, 107*f*, 108  
 relaxin and systemic vascular resistance, 25–26  
 renal function impairment, 20, 230  
 Renal Interlobar Vein Impedance index (RIVI), 38, 86, 87–88, 89  
 respiratory movements, 36  
 resting cardiac output, 15–17  
 retinal vessel analysis, 48*f*, 49*f*  
 right ventricular dimensions/mass, 27  
  
 salt-sensitive hypertension, 151  
 secondary hypertension, 147  
 sidestream dark field imaging technique (SDF), 45  
 Sildenafil citrate (SC), 187, 196–197  
 Simpson's (modified) biplane technique, 122*f*  
 single plane B-mode 4-chamber view, 122, 123*f*  
 small for gestational age (SGA), 74  
 S-nitrosoglutathione (GSNO), 153, 185*f*, 186  
 S-nitrosothiols, 185*f*, 186  
 sodium and water retention, 14  
 sodium nitroprusside, 96, 184  
  
 soluble guanylatecyclase (sGC), 195  
 SphygmoCor system, 108  
 Starling's principle, 43  
 steady component in systemic vascular resistance, 25  
 stroke volume (SV), 25  
 subsequent impaired placental perfusion, 1  
 suprasternal Doppler, 125–126  
 Swedish cohort study on CVD, 231  
 sympathetic nervous system, 34, 35  
 syncytiotrophoblast microparticles, 91, 210  
 systemic microcirculation, 17*f*, 18, 22  
   vascular relaxation, 15, 16*f*, 16*t*, 22  
   vascular resistance, 25–26  
 systolic blood pressure (SBP), 24, 71, 74, 109  
   function, 29, 81–82  
   myocardial deformation, 30  
  
 target vessel revascularization (TVR), 81  
 teenage pregnancies, 233  
 Teichholz method, 121  
 temporal classification of preeclampsia  
   clinical diagnoses of hypertensive disorders of pregnancy, 210–213, 211*f*, 212*f*, 214*f*  
   clinical phenotypes, 205–206  
   maternal-fetal medicine (MFM) and preeclampsia, 207–209, 208*t*, 209*f*  
   therapeutic angiogenesis, 171  
   3-D echocardiography, 123–125  
 thromboembolic deterrent (TED) stockings, 144  
 thromboxane A<sub>2</sub> (TXA<sub>2</sub>), 161, 162, 164  
 tissue Doppler imaging (TDI), 30  
 triplane analysis, 122, 124*f*  
 trisomic pregnancies, 3  
 trophoblast development, 1  
 trophoblast function, 164  
 tumor necrosis factor- $\alpha$  levels, 94  
  
 ultrasound devices, 108  
 United Kingdom Confidential Enquiries into Maternal and Child Death, 154  
 unresolved clinical dilemmas, 167–168  
 uterine artery Doppler screening, 4, 5, 165, 210–211, 212*f*  
   injection, 175  
   pulsatility index, 74  
 uteroplacental blood flow (UBF), 21, 31, 161, 164–165  
  
 valsalva maneuver, 88  
 vascular endothelial growth factor (VEGF)  
   adverse pregnancy outcome, 173  
   aspirin and, 163  
   current medical use, 174  
   delivery method, 177  
   ethics and safety of, 177–178  
   fetal growth restriction and, 171, 174–178, 176*f*, 177*f*  
   normal fetal growth and, 172*f*, 172, 173  
   placental growth factor, 182–183  
   preclinical studies, 175, 176*f*, 177*f*  
   pregnancy as ideal vector, 175  
 vascular histological lesions of the placenta, 2–3, 70  
 vasculogenesis, 172*f*, 172  
 vasoactive substances, 91  
 vasodilation, 151  
 venous compartment in normal pregnancy, 18, 19*f*, 22  
   capillary function, 36  
   direct stimulation, 35  
   future research, 39  
   indirect stimulation, 35–36  
   plasma volume, 63  
   in pregnancy, 38–39  
   venous Doppler waveform, 36, 37*f*, 38*f*  
   venous physiology, 35  
   venous system, 34–35  
 venous Doppler sonography improving reproductability, 116–117  
   limitations and pitfalls, 117  
   practical aspects of, 113, 114*f*, 116*f*

- venous Doppler waveform  
 experimentally induced  
 changes, 88  
 hepatic veins (HV)  
 waveforms, 87*f*, 87  
 non-proteinuric gestational  
 hypertension, 88–89  
 overview of, 36, 37*f*, 38*f*  
 preeclampsia and,  
 86–88, 89  
 Renal Interlobar Vein  
 Impedance index, 86,  
 87–88, 89  
 Venous Pulse Transit Time,  
 86, 88  
 venous impedance index,  
 37, 38
- occlusion  
 plethysmography, 103  
 peak velocity, 115  
 physiology, 35  
 pre-acceleration nadir,  
 86, 87  
 Pulse Transit Time, 86,  
 88, 116  
 reserves and plasma volume  
 changes, 59–61, 60*f*  
 ventricular (LV) dimension,  
 6, 121  
 ventricular remodeling, 5  
 vessel density (VD), 45  
 Vicorder system, 108  
 video capillaroscopy, 44,  
 45–46, 93
- villous histological lesions of  
 the placenta, 2–3  
 visco-elastic tube, 103  
 vitamin  
 C supplementation, 152  
 vitamin  
 E supplementation, 152  
 volume clamp technique, 128  
 volume homeostasis effects,  
 19–20
- wavelength change (Doppler  
 shift), 46  
 weight gain, 229  
 wick-in-needle technique, 95  
 World Health Organization  
 (WHO), 206